CIRM asks patients how to spend last $800m for stem cell therapies
This article was originally published in Scrip
The California Institute for Regenerative Medicine (CIRM) is asking patient advocates how the agency should spend the last $800m of the $3bn that the state raised through bond sales to fund stem cell research, and the answer at a recent hearing in San Diego wasn't surprising: "Spend it on me."
You may also be interested in...
Private Company Edition: Investments by CIRM, the GHIT fund and the European Investment Bank back early-stage science and treatments for neglected diseases. Also, Versant Ventures raises $700m in two funds. In VC deals, Akero raised $70m, Impel NeuroPharma brought in $67.5m.
Private Company Edition: Jeito says its new first fund is Europe’s largest life science-focused fund. Illumina will use its venture capital to support tools, diagnostics, therapeutics and more. Also, IASO closed a $108m series C round and Amolyt raised $80m in series C financing.
In an attempt to show Biogen has more than its troubled Alzheimer’s drug Aduhelm to drive revenue growth, the company’s R&D Day highlighted several programs from its portfolio of 33 clinical-stage assets.